Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesDividends payablesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Vycor Medical (VYCO) Cash & Equivalents (2016 - 2025)

Vycor Medical has reported Cash & Equivalents over the past 16 years, most recently at $86982.0 for Q4 2025.

  • Quarterly Cash & Equivalents fell 17.67% to $86982.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $86982.0 through Dec 2025, down 17.67% year-over-year, with the annual reading at $86982.0 for FY2025, 17.67% down from the prior year.
  • Cash & Equivalents was $86982.0 for Q4 2025 at Vycor Medical, up from $64230.0 in the prior quarter.
  • Over five years, Cash & Equivalents peaked at $157633.0 in Q3 2024 and troughed at $32570.0 in Q3 2022.
  • The 5-year median for Cash & Equivalents is $66642.5 (2023), against an average of $73849.3.
  • Year-over-year, Cash & Equivalents crashed 59.87% in 2022 and then soared 128.27% in 2024.
  • A 5-year view of Cash & Equivalents shows it stood at $90941.0 in 2021, then crashed by 59.28% to $37035.0 in 2022, then surged by 54.69% to $57291.0 in 2023, then surged by 84.41% to $105648.0 in 2024, then fell by 17.67% to $86982.0 in 2025.
  • Per Business Quant, the three most recent readings for VYCO's Cash & Equivalents are $86982.0 (Q4 2025), $64230.0 (Q3 2025), and $99700.0 (Q2 2025).